Kissei

Kissei Pharmaceutical
ISIN	JP3240600001
Industry	Pharmaceutical products, therapeutic and care foods
Founded	August 9, 1946; 78 years ago
Headquarters	Matsumoto, Nagano, Japan
Key people	Mutsuo Kanzawa (CEO)
Number of employees	1504
Website	www.kissei.co.jp/e_contents/

Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:^[1]

Difelikefalin
Fostamatinib (trade name Tavalisse)
Linzagolix
Mitiglinide (Glufast)
Remogliflozin etabonate
Silodosin (Urief)
Tranilast (Rizaben)

In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immumotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China.^[2]

References

^ https://www.kissei.co.jp/e_contents/
^ "CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries". www.businesswire.com. 2020-03-27. Retrieved 2020-06-04.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This corporation or company article is a stub. You can help Wikipedia by expanding it.

[1] ttps://www.kissei.co.jp/e_contents/

[2] "CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries". www.businesswire.com. 2020-03-27. Retrieved 2020-06-04.

[1]

[2]